Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

541.89
+60.4212.55%
Post-market: 542.000.1100+0.02%19:51 EDT
Volume:3.34M
Turnover:1.79B
Market Cap:23.24B
PE:19.39
High:557.37
Open:482.20
Low:475.46
Close:481.47
52wk High:609.35
52wk Low:409.07
Shares:42.89M
Float Shares:39.35M
Volume Ratio:6.52
T/O Rate:8.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.63
PE(LYR):19.45

Loading ...

United Therapeutics CEO Martine Rothblatt Reports $ 4.45 Million Common Share Disposal

Reuters
·
Jul 21

United Therapeutics CEO Martine Rothblatt Reports UTHR Common Share Sale Worth $4.97 Million

Reuters
·
Jul 18

United Therapeutics (UTHR) Stock Still Looks Like A Bargain After A 185% Run

Simply Wall St.
·
Jul 18

United Therapeutics EVP, General Counsel Paul A. Mahon Disposes of Common Shares Worth $3.97 Million

Reuters
·
Jul 17

United Therapeutics CEO Martine Rothblatt Disposes of 9,500 Shares for $5,008,396.54

Reuters
·
Jul 16

United Therapeutics Chairperson, CEO Martine Rothblatt Sells USD 4.89 Million in Common Shares

Reuters
·
Jul 15

United Therapeutics CEO Martine Rothblatt Disposes of USD 3.29 Million in Common Shares

Reuters
·
Jul 14

United Therapeutics Director Jan Malcolm Sells 325 Shares for $178,941.75

Reuters
·
Jul 11

United Therapeutics is Maintained at Neutral by B of a Securities

Dow Jones
·
Jul 11

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires Live
·
Jul 11

BETA Technologies Completes First FAA Evtol Integration Pilot Flights Carrying Manufactured Organs

Reuters
·
Jul 11

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 10

BofA Securities Adjusts United Therapeutics Price Target to $613 From $620

MT Newswires Live
·
Jul 10

United Therapeutics price target lowered to $613 from $620 at BofA

TIPRANKS
·
Jul 10

United Therapeutics CEO Martine Rothblatt Disposes of USD 5.18 Million in Common Shares

Reuters
·
Jul 09

What United Therapeutics (UTHR)'s Centralized LungFX EVLP FDA Approval Means For Shareholders

Simply Wall St.
·
Jul 08

United Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 08

United Therapeutics CEO Martine Rothblatt Sells 9,500 Common Shares for $5.21 Million

Reuters
·
Jul 07

RBC Capital Raises United Therapeutics Price Target to $704 From $701, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

United Therapeutics CEO Martine Rothblatt Disposes of 8,500 Common Shares Worth $4.63 Million

Reuters
·
Jul 03